Natixis Acquires 80,000 Shares of Hologic, Inc. (NASDAQ:HOLX)

Natixis increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 497.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 96,080 shares of the medical equipment provider's stock after acquiring an additional 80,000 shares during the period. Natixis' holdings in Hologic were worth $6,926,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of HOLX. Brooklyn Investment Group grew its holdings in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after acquiring an additional 145 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares during the last quarter. Trivant Custom Portfolio Group LLC grew its stake in Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock valued at $602,000 after purchasing an additional 169 shares in the last quarter. UMB Bank n.a. increased its position in shares of Hologic by 4.1% during the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock worth $343,000 after purchasing an additional 188 shares during the last quarter. Finally, Capital Investment Counsel Inc raised its stake in shares of Hologic by 3.6% during the 4th quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock worth $413,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Stock Down 0.5 %

Shares of HOLX traded down $0.27 during trading hours on Friday, reaching $58.02. 1,814,347 shares of the stock traded hands, compared to its average volume of 1,963,150. The company has a market cap of $13.02 billion, a price-to-earnings ratio of 18.30, a PEG ratio of 2.14 and a beta of 0.82. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a fifty day simple moving average of $61.14 and a 200 day simple moving average of $70.22. Hologic, Inc. has a 52 week low of $55.89 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

HOLX has been the subject of several analyst reports. Raymond James reissued an "outperform" rating and issued a $90.00 target price (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Royal Bank of Canada dropped their target price on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a report on Thursday, February 6th. Needham & Company LLC lowered Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective on the stock. in a research note on Monday, February 3rd. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Finally, William Blair reissued an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Hologic has a consensus rating of "Hold" and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.